Prevention of UV- Induced Apoptosis by Caffeine (Caff2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03534973 |
|
Recruitment Status : Unknown
Verified October 2019 by Prim. Prof. Dr. Oliver Findl, MBA, Vienna Institute for Research in Ocular Surgery.
Recruitment status was: Recruiting
First Posted : May 23, 2018
Last Update Posted : October 2, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cataract | Other: Caffeine intake Other: No caffeine intake | Not Applicable |
Caffeine is a worldwide consumed dietary constituent. It occurs in a variety of beverages such as coffee, tea, soft drinks and cocoa beverages, and in chocolate-based food products. In the United States there is a reported average intake of caffeine of 200 mg/d in 80 % of adults corresponding to the amount in two 5-ounce cups of coffee or four sodas. A new interest for caffeine in ophthalmology emerged with the observation that caffeine inhibits cataractogenesis.
Cataract is the leading cause of blindness worldwide and until now there is no approved drug to prevent cataract. UVR-B radiation has been identified as one of the major risk factors for age related cataract. In vitro, Varma showed that caffeine preserves ATP levels and GSH levels in the lens when exposed to UVR-B and further maintains the state of transparency in the lens. Varma moreover hypothesized that its protective effect in the lens is due to its ability to scavenge reactive oxygen species (ROS) and to suppress elevation of toxic microRNAs and consequent gene silencing. In the galactosemic rat model, Varma demonstrated that topical caffeine in vivo inhibited the formation of galactose cataract and prevented apoptosis of lens epithelial cells.
A further study presented evidence that topical caffeine also prevents in vivo UVR-B induced cataract and inhibits apoptosis of lens epithelial cells. The investigators estimated the protection factor (PF) of caffeine to 1.23. The PF is identical to PF for sunscreens; the ratio between the threshold dose of the toxic agent and the threshold dose without the toxic agent. The PF observed for topically applied caffeine was higher than the PF observed for perorally administered vitamin E (PF: 1.14) and vitamin C (PF: 1) , respectively. Only the Grx gene provides a higher PF (PF 1.3). This strongly supports that caffeine has an important antioxidant capacity in vivo.
Up to 99 % of caffeine is gastrointestinally absorbed and pharmacokinetics are comparable after oral and i.v. administration. In the liver, caffeine is metabolized by hepatic enzymes belonging to the cytochrome P-450 family, mainly CYP1A2. Major metabolites like 1-methylxanthine and 1-methyl uric acid were reported to still have significant antioxidant activity. Recently, a study confirmed the protective effect of coffee combined with additional antioxidant dietary against age-related cataract. Its hydrophobic properties allow caffeine passage over all biological membranes. A further study found that caffeine after oral intake accumulates in the lens epithelium.
The lens epithelium plays a major role in balancing water, ions and the metabolic homeostasis. Additionally, the germinative cells in the lens epithelium generate a reservoir for lens fiber cell generation. UVR-B radiation is absorbed by proteins and DNA in the lens epithelium and underlying lens fibres, causing damage to the cells. When epithelial cells are damaged, lens growth and transparency is disturbed. Michael et al. demonstrated the appearance of apoptotic lens cells after in vivo exposure to UVR-B with transmission electron microscopy. No necrotic cells were found at threshold dose. We found a peak of Apoptosis hours after UVR-B exposure.
The present study aims to investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Prevention of Experimental Ultraviolet Induced Apoptosis in Explanted Human Lens Epithelial Cells Enriched With Caffeine: a Pilot Study |
| Actual Study Start Date : | April 17, 2018 |
| Estimated Primary Completion Date : | December 1, 2019 |
| Estimated Study Completion Date : | January 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Caffeine intake
Caffeine is given orally prior to cataract surgery
|
Other: Caffeine intake
Cataract surgery in eyes with prior caffeine intake |
|
Sham Comparator: No caffeine intake
Caffeine is not given orally prior to cataract surgery
|
Other: No caffeine intake
Cataract surgery in eyes without prior caffeine intake |
- Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake [ Time Frame: 12 months ]Using a cell apoptosis and viability assay the number of apoptotic and viable lens epithelial cells is counted under a fluorescence microscope
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years to 105 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 21 years
- Cataract
- Patients who chose pseudoanalgesia technique for cataract surgery before recruitment process
- Written informed consent prior to surgery
Exclusion Criteria:
- Age < 21 years
- Beverages containing caffeine (such as Coffee, Coca Cola, energy drinks, black or green tea) and dark chocolate consumption 1 week before surgery
- Pseudoexfoliation syndrome of the lens
- Systolic hypertension of >160 at the day of surgery
- Pregnancy (pregnancy test will be taken in women of reproductive age)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534973
| Contact: Martin Kronschlaeger, MD | 01 91021-57572 | martin.kronschlaeger@gmx.at | |
| Contact: Manuel Ruiß, MSc | 01 91021-57564 | m.ruiss@viros.at |
| Austria | |
| Vienna Institute for Research in Ocular Surgery (VIROS) | Recruiting |
| Vienna, Austria, 1140 | |
| Contact: Martin Kronschlaeger, MD 01 91021-57572 martin.kronschlaeger@gmx.at | |
| Contact: Manuel Ruiß, Mac 01 90121-57564 m.ruiss@viros.at | |
| Responsible Party: | Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery |
| ClinicalTrials.gov Identifier: | NCT03534973 |
| Other Study ID Numbers: |
Caff2 |
| First Posted: | May 23, 2018 Key Record Dates |
| Last Update Posted: | October 2, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cataract Caffeine |
|
Cataract Lens Diseases Eye Diseases Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |